FY2025 EPS Estimates for Vaxcyte Cut by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has decreased its FY2025 earnings per share estimate for Vaxcyte to ($5.50), down from ($5.10), while maintaining an "Overweight" rating on the stock.
• Vaxcyte reported a quarterly loss of ($1.22) EPS, which missed analysts' expectations of ($1.12), reflecting ongoing challenges in achieving profitability.
• Despite the downward revision in earnings estimates, Vaxcyte maintains a consensus rating of "Buy" from ten investment analysts, with a target price of $136.50.

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Vaxcyte in a research report issued to clients and investors on Thursday, August 7th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will post earnings per share of ($5.50) for the year, down from their prior forecast of ($5.10). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Cantor Fitzgerald also issued estimates for Vaxcyte's FY2026 earnings at ($7.28) EPS.

Separately, Cowen reaffirmed a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $136.50.

Vaxcyte Price Performance

NASDAQ PCVX traded up $0.02 on Monday, hitting $31.57. The company had a trading volume of 422,155 shares, compared to its average volume of 1,786,168. The company has a market capitalization of $4.10 billion, a PE ratio of -7.66 and a beta of 1.21. The company's fifty day moving average price is $34.18 and its 200-day moving average price is $47.48. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business posted ($1.10) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN lifted its position in Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after buying an additional 25,257 shares during the last quarter. Rhumbline Advisers lifted its position in Vaxcyte by 5.5% in the first quarter. Rhumbline Advisers now owns 181,230 shares of the company's stock valued at $6,843,000 after buying an additional 9,416 shares during the last quarter. Parallel Advisors LLC lifted its position in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after buying an additional 1,071 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Vaxcyte by 12.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock valued at $4,509,000 after buying an additional 6,121 shares during the last quarter. Finally, Barclays PLC lifted its position in Vaxcyte by 19.1% in the fourth quarter. Barclays PLC now owns 254,885 shares of the company's stock valued at $20,865,000 after buying an additional 40,932 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.